Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update
March 23, 2023 16:05 ET
|
Gain Therapeutics, Inc.
Company expects completion of IND-enabling studies of GT-02287 in H1 2023Submission of dossier to start Phase 1 clinical trial of GT-02287 in GBA1 Parkinson’s Disease expected by mid-year 2023$22.1...
Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders
March 22, 2023 08:30 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., March 22, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program
March 21, 2023 08:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., March 21, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX), a biotechnology company transforming drug discovery with its proprietary computational discovery platform...
Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference
March 09, 2023 08:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., March 09, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium
February 27, 2023 08:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences
February 02, 2023 08:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference
January 12, 2023 16:05 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update
November 10, 2022 16:02 ET
|
Gain Therapeutics, Inc.
Presented New Preclinical Data at Recent Medical Meetings Showing Disease-Modifying Potential of Brain Penetrant Small Molecule Parkinson’s Disease Therapeutic, GT-02287 Promoted Matthias Alder...
Gain Therapeutics Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson’s Disease Patient-Derived Dopaminergic Neurons
September 26, 2022 08:00 ET
|
Gain Therapeutics, Inc.
Accumulating Preclinical Data Provide Further Support for Disease-Modifying Potential of Brain Penetrant Investigational Small Molecule Therapeutic, GT-02287 Results Presented at the Shaare Zedek...
Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer
September 20, 2022 07:30 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...